Johns Hopkins ABX Guide
Ozenoxacin
INDICATIONS
FDA
FDA
- Topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients ≥ 2 months of age.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: February 10, 2020
Citation
Dzintars, Kathryn. "Ozenoxacin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2020. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540730/5.0/Ozenoxacin.
Dzintars K. Ozenoxacin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540730/5.0/Ozenoxacin. Accessed October 31, 2025.
Dzintars, K. (2020). Ozenoxacin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540730/5.0/Ozenoxacin
Dzintars K. Ozenoxacin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. [cited 2025 October 31]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540730/5.0/Ozenoxacin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ozenoxacin
ID - 540730
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2020/02/10/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540730/5.0/Ozenoxacin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
